157 related articles for article (PubMed ID: 37741968)
1. Clinical trial protocol for PanDox: a phase I study of targeted chemotherapy delivery to non-resectable primary pancreatic tumours using thermosensitive liposomal doxorubicin (ThermoDox®) and focused ultrasound.
Spiers L; Gray M; Lyon P; Sivakumar S; Bekkali N; Scott S; Collins L; Carlisle R; Wu F; Middleton M; Coussios C
BMC Cancer; 2023 Sep; 23(1):896. PubMed ID: 37741968
[TBL] [Abstract][Full Text] [Related]
2. Clinical trial protocol for TARDOX: a phase I study to investigate the feasibility of targeted release of lyso-thermosensitive liposomal doxorubicin (ThermoDox®) using focused ultrasound in patients with liver tumours.
Lyon PC; Griffiths LF; Lee J; Chung D; Carlisle R; Wu F; Middleton MR; Gleeson FV; Coussios CC
J Ther Ultrasound; 2017; 5():28. PubMed ID: 29118984
[TBL] [Abstract][Full Text] [Related]
3. Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.
Lyon PC; Gray MD; Mannaris C; Folkes LK; Stratford M; Campo L; Chung DYF; Scott S; Anderson M; Goldin R; Carlisle R; Wu F; Middleton MR; Gleeson FV; Coussios CC
Lancet Oncol; 2018 Aug; 19(8):1027-1039. PubMed ID: 30001990
[TBL] [Abstract][Full Text] [Related]
4. Large-Volume Hyperthermia for Safe and Cost-Effective Targeted Drug Delivery Using a Clinical Ultrasound-Guided Focused Ultrasound Device.
Lyon PC; Mannaris C; Gray M; Carlisle R; Gleeson FV; Cranston D; Wu F; Coussios CC
Ultrasound Med Biol; 2021 Apr; 47(4):982-997. PubMed ID: 33451816
[TBL] [Abstract][Full Text] [Related]
5. Phase I feasibility study of Magnetic Resonance guided High Intensity Focused Ultrasound-induced hyperthermia, Lyso-Thermosensitive Liposomal Doxorubicin and cyclophosphamide in
de Maar JS; Suelmann BBM; Braat MNGJA; van Diest PJ; Vaessen HHB; Witkamp AJ; Linn SC; Moonen CTW; van der Wall E; Deckers R
BMJ Open; 2020 Nov; 10(11):e040162. PubMed ID: 33243800
[TBL] [Abstract][Full Text] [Related]
6. Enhanced drug delivery in rabbit VX2 tumours using thermosensitive liposomes and MRI-controlled focused ultrasound hyperthermia.
Staruch RM; Ganguly M; Tannock IF; Hynynen K; Chopra R
Int J Hyperthermia; 2012; 28(8):776-87. PubMed ID: 23153219
[TBL] [Abstract][Full Text] [Related]
7. Focused Ultrasound Hyperthermia for Targeted Drug Release from Thermosensitive Liposomes: Results from a Phase I Trial.
Gray MD; Lyon PC; Mannaris C; Folkes LK; Stratford M; Campo L; Chung DYF; Scott S; Anderson M; Goldin R; Carlisle R; Wu F; Middleton MR; Gleeson FV; Coussios CC
Radiology; 2019 Apr; 291(1):232-238. PubMed ID: 30644817
[TBL] [Abstract][Full Text] [Related]
8. Hyperthermia-mediated doxorubicin release from thermosensitive liposomes using MR-HIFU: therapeutic effect in rabbit Vx2 tumours.
Staruch RM; Hynynen K; Chopra R
Int J Hyperthermia; 2015 Mar; 31(2):118-33. PubMed ID: 25582131
[TBL] [Abstract][Full Text] [Related]
9. Focused Ultrasound Hyperthermia Mediated Drug Delivery Using Thermosensitive Liposomes and Visualized With
Santos MA; Goertz DE; Hynynen K
Theranostics; 2017; 7(10):2718-2731. PubMed ID: 28819458
[TBL] [Abstract][Full Text] [Related]
10. Effects of human tissue acoustic properties, abdominal wall shape, and respiratory motion on ultrasound-mediated hyperthermia for targeted drug delivery to pancreatic tumors.
Gray M; Spiers L; Coussios C
Int J Hyperthermia; 2022 Dec; 39(1):918-934. PubMed ID: 35853611
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
Reni M; Balzano G; Zanon S; Zerbi A; Rimassa L; Castoldi R; Pinelli D; Mosconi S; Doglioni C; Chiaravalli M; Pircher C; Arcidiacono PG; Torri V; Maggiora P; Ceraulo D; Falconi M; Gianni L
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):413-423. PubMed ID: 29625841
[TBL] [Abstract][Full Text] [Related]
12. Drug development of lyso-thermosensitive liposomal doxorubicin: Combining hyperthermia and thermosensitive drug delivery.
Borys N; Dewhirst MW
Adv Drug Deliv Rev; 2021 Nov; 178():113985. PubMed ID: 34555486
[TBL] [Abstract][Full Text] [Related]
13. Tumour-specific fluorescence-guided surgery for pancreatic cancer using panitumumab-IRDye800CW: a phase 1 single-centre, open-label, single-arm, dose-escalation study.
Lu G; van den Berg NS; Martin BA; Nishio N; Hart ZP; van Keulen S; Fakurnejad S; Chirita SU; Raymundo RC; Yi G; Zhou Q; Fisher GA; Rosenthal EL; Poultsides GA
Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):753-764. PubMed ID: 32416764
[TBL] [Abstract][Full Text] [Related]
14. Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol.
Karbhari A; Mosessian S; Trivedi KH; Valla F; Jacobson M; Truty MJ; Patnam NG; Simeone DM; Zan E; Brennan T; Chen H; Kuo PH; Herrmann K; Goenka AH
PLoS One; 2023; 18(11):e0294564. PubMed ID: 38011131
[TBL] [Abstract][Full Text] [Related]
15. Triple modal treatment comprising with proton beam radiation, hyperthermia, and gemcitabine/nab-paclitaxel for locally advanced pancreatic cancer: a phase I/II study protocol (TT-LAP trial).
Shimomura O; Endo M; Makishima H; Yamada T; Hashimoto S; Numajiri H; Miyazaki Y; Doi M; Furuya K; Takahashi K; Moriwaki T; Hasegawa N; Yamamoto Y; Niisato Y; Kobayashi M; Mizumoto M; Nakai K; Saito T; Hoshiai S; Saida T; Mathis BJ; Mori K; Nakajima T; Tsuchiya K; Sakurai H; Oda T
BMC Cancer; 2023 Jul; 23(1):624. PubMed ID: 37403011
[TBL] [Abstract][Full Text] [Related]
16. Image-guided thermosensitive liposomes for focused ultrasound drug delivery: Using NIRF-labelled lipids and topotecan to visualise the effects of hyperthermia in tumours.
Centelles MN; Wright M; So PW; Amrahli M; Xu XY; Stebbing J; Miller AD; Gedroyc W; Thanou M
J Control Release; 2018 Jun; 280():87-98. PubMed ID: 29723616
[TBL] [Abstract][Full Text] [Related]
17. MR-labelled liposomes and focused ultrasound for spatiotemporally controlled drug release in triple negative breast cancers in mice.
Amrahli M; Centelles M; Cressey P; Prusevicius M; Gedroyc W; Xu XY; So PW; Wright M; Thanou M
Nanotheranostics; 2021; 5(2):125-142. PubMed ID: 33457192
[No Abstract] [Full Text] [Related]
18. Pulsed High-Intensity Focused Ultrasound Enhances Delivery of Doxorubicin in a Preclinical Model of Pancreatic Cancer.
Li T; Wang YN; Khokhlova TD; D'Andrea S; Starr F; Chen H; McCune JS; Risler LJ; Mashadi-Hossein A; Hingorani SR; Chang A; Hwang JH
Cancer Res; 2015 Sep; 75(18):3738-46. PubMed ID: 26216548
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
[TBL] [Abstract][Full Text] [Related]
20. Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer.
Mikhail AS; Negussie AH; Pritchard WF; Haemmerich D; Woods D; Bakhutashvili I; Esparza-Trujillo J; Brancato SJ; Karanian J; Agarwal PK; Wood BJ
Int J Hyperthermia; 2017 Nov; 33(7):733-740. PubMed ID: 28540814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
